JPMorgan has increased its price target for Tyson Foods (TSN) to $67, up from $63, while maintaining a Neutral rating. The adjustment follows the company's latest earnings, which highlighted persistent struggles in its beef segment alongside brighter spots in other divisions.
PayPal announces leadership shakeup, with CFO Jamie Miller stepping in as interim CEO after Alex Chriss's departure, while naming HP's Enrique Lores as permanent chief from March 1, as the payments giant grapples with an 80% stock decline over five years.
Analysts have nudged the fair value estimate for pharmaceutical player Laurus Labs higher by approximately 6%, a move interpreted less as a major revision and more as a reaffirmation of faith in the company's existing growth trajectory.
Financial firm Rothschild & Co. Redburn has downgraded PayPal Holdings Inc. (PYPL) from Neutral to Sell, slashing its price target to $50, citing concerns over eroding market share in the face of aggressive competition from newer payment platforms.
BitMine Immersion Technologies (BMNR) shares continue their sharp decline, shedding nearly a third of their value in a month, as investors flee despite the chairman's defense of the company's massive unrealized losses on its Ethereum holdings. Technical indicators and a breakdown in chart structure suggest the sell-off has further to run.
The pharmaceutical giant AbbVie projects profits exceeding analyst expectations for 2026, buoyed by the stellar performance of its newer immunology drugs Skyrizi and Rinvoq, which are successfully offsetting the decline of its former top-seller Humira.
The Danish pharmaceutical giant warns of its first sales decline in years for 2026, citing U.S. pricing pressures and patent expirations, sending shockwaves through investor confidence and highlighting intensifying competition in the lucrative obesity drug market.
Amid a sharp downturn in crypto markets, Cathie Wood's ARK Invest has made significant purchases of crypto-linked equities, including a major stake in BitMine. The move comes as BitMine Chairman Tom Lee publicly defends the firm's long-term Ethereum strategy despite substantial paper losses.
GE HealthCare Technologies posted stronger-than-expected fourth-quarter revenue of $5.70 billion, a 7.1% year-over-year increase, while adjusted earnings per share of $1.44 also edged past analyst consensus. The performance highlights steady demand for its medical imaging and pharmaceutical diagnostics units amid ongoing healthcare capital investment.
Pharmaceutical giant Eli Lilly (LLY) smashed Wall Street forecasts with a 42.6% surge in Q4 revenue to $19.29 billion, sending its stock sharply higher. The company also issued robust full-year guidance, underscoring the transformative impact of its new generation of therapies.
New data from the luxury watch marketplace reveals a decisive pivot among collectors towards refined aesthetics and classic design, signaling a cooling of speculative frenzy and the return of the connoisseur.
Facing intensifying competition for its blockbuster drugs Wegovy and Ozempic, Danish pharmaceutical leader Novo Nordisk has issued a sobering sales outlook for 2026, projecting its first annual decline since 2017 and triggering a sharp stock sell-off.
A deadly collision off the coast of Chios has left at least 15 migrants dead and sparked a major search operation, highlighting the ongoing perils of Mediterranean migration routes amid tightening EU policies.
Fugro has mobilized a significant fleet to conduct a comprehensive geotechnical survey for TotalEnergies' 2GW NordSee Energies 1 project, a key development in Germany's offshore wind expansion and Europe's push for energy security.
Shell has agreed to sell a 20% stake in Brazil's deepwater Orca Project to Kuwait Foreign Petroleum Exploration Company (KUFPEC), reinforcing a long-standing energy partnership while maintaining operatorship and a 50% holding in the key pre-salt asset.
In his latest investor letter, hedge fund veteran David Einhorn warns that soaring market valuations, driven by AI euphoria and rampant speculation, echo past bubbles. While advocating for caution, he also reveals new value-oriented bets for his Greenlight Capital.
Regulatory milestones for two AstraZeneca cancer drugs—one in the U.S. and one in Europe—signal momentum for the pharma giant's targeted oncology pipeline, offering new hope for patients with difficult-to-treat cancers.
As Denali Therapeutics prepares to present new data on its blood-brain barrier platform at a major symposium, the company faces a pivotal moment with an upcoming FDA decision. Investors are weighing promising science against financial pressures and execution risks.
Amid a broader market selloff, Standard Chartered advises investors to look beyond short-term volatility and accumulate positions in high-quality blockchain projects like Ethereum and Solana, viewing the downturn as a strategic entry point for long-term gains.
In a stark earnings call, Palantir CEO Alex Karp framed the AI race as a clash between 'haves' and 'have-nots,' citing explosive U.S. growth and warning that reluctance in Canada and Europe could trigger political upheaval.
